Abatacept News and Research

RSS
Abatacept (marketed as Orencia) is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4, a molecule capable of binding B7. Abatacept is a selective costimulation modulator as it inhibits the costimulation of T cells. It was developed by Bristol-Myers-Squibb and is licensed in the United States for the treatment of rheumatoid arthritis in the case of inadequate response to anti-TNFa therapy.
Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Study describes lack of positive effects in drugs, long-term data and robust direct comparisons in RA

Updated EULAR recommendations for management of rheumatoid arthritis

Updated EULAR recommendations for management of rheumatoid arthritis

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

AMPLE trial demonstrates similar safety profiles and efficacy between abatacept and adalimumab in RA

University of Cincinnati to lead Belatacept Early Steroid withdrawal Trial

University of Cincinnati to lead Belatacept Early Steroid withdrawal Trial

'No malignancy risk' with biologic response modifiers

'No malignancy risk' with biologic response modifiers

Data from abatacept versus adalimumab Phase IIIb comparison study on RA

Data from abatacept versus adalimumab Phase IIIb comparison study on RA

Bristol-Myers Squibb receives FDA approval for Devens facility to produce ORENCIA

Bristol-Myers Squibb receives FDA approval for Devens facility to produce ORENCIA

New guidelines offer guidance on how and when to switch between RA drug classes

New guidelines offer guidance on how and when to switch between RA drug classes

Juvenile arthritis affected kids are at a high risk of cancer: Study

Juvenile arthritis affected kids are at a high risk of cancer: Study

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

Ono, Bristol-Myers Squibb partner to develop BMS-936558/ONO-4538 and ORENCIA

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

ORENCIA SC formulation receives FDA approval for treatment of adults with RA

New clinical practice guidelines developed for juvenile idiopathic arthritis

New clinical practice guidelines developed for juvenile idiopathic arthritis

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

Phase II trial finds fostamatinib ineffective in RA patients not responsive to biologic agents

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

FDA accepts for review Bristol-Myers Squibb's ORENCIA sBLA for severe RA

Further trials needed to determine clinical application of Abatacept in SLE

Further trials needed to determine clinical application of Abatacept in SLE

European Commission approves new indication for ORENCIA in combination with MTX for RA

European Commission approves new indication for ORENCIA in combination with MTX for RA

New report on launch trend of Roche's Actemra

New report on launch trend of Roche's Actemra

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Clinical data supports continued development of ORENCIA administration for rheumatoid arthritis

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers

More studies needed to compare the efficacy of different biologic drugs for RA, say researchers